NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $44.53 +1.83 (+4.29%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$42.84▼$44.8850-Day Range$30.01▼$44.5352-Week Range$6.40▼$45.46Volume954,919 shsAverage Volume1.65 million shsMarket Capitalization$3.89 billionP/E RatioN/ADividend YieldN/APrice Target$43.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Dyne Therapeutics alerts: Email Address Dyne Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside3.2% Downside$43.11 Price TargetShort InterestBearish10.57% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.14Based on 4 Articles This WeekInsider TradingSelling Shares$6.50 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.00) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector763rd out of 936 stocksPharmaceutical Preparations Industry354th out of 436 stocks 2.6 Analyst's Opinion Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.57% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Dyne Therapeutics has recently increased by 1.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYN. Previous Next 2.9 News and Social Media Coverage News SentimentDyne Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Dyne Therapeutics this week, compared to 4 articles on an average week.Search Interest17 people have searched for DYN on MarketBeat in the last 30 days. This is an increase of 143% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,500,387.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.00) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 29.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Dyne Therapeutics Stock (NASDAQ:DYN)Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More DYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYN Stock News HeadlinesJuly 18, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month High at $44.30June 24, 2024 | globenewswire.comDyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe DiseaseJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 13, 2024 | globenewswire.comDyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research CongressMay 30, 2024 | globenewswire.comDyne Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesMay 23, 2024 | bizjournals.comThe Petri Dish: Dyne’s public offering, Kronos’ new CFOMay 22, 2024 | forbes.comUp 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 22, 2024 | markets.businessinsider.comDyne Therapeutics Prices Public Offering Of 10.50 Mln Shares At $31.00/shrMay 21, 2024 | globenewswire.comDyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockMay 21, 2024 | seekingalpha.comDyne Therapeutics: Progress Undenied In DM1 And DMD TrialsMay 21, 2024 | finance.yahoo.comAnnouncement of The Shaw Laureates 2024May 20, 2024 | msn.comWhy Is Dyne Therapeutics Stock Soaring On Monday?May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dyne Therapeutics (DYN)May 20, 2024 | finance.yahoo.comWhy Dyne Therapeutics, With A 166% Run This Year, Just Catapulted AgainMay 20, 2024 | globenewswire.comDyne Therapeutics Announces Proposed Public Offering of Common StockMay 20, 2024 | marketwatch.comDyne Therapeutics Shares Rise 23% on Favorable Drug DataSee More Headlines Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$43.11 High Stock Price Target$56.00 Low Stock Price Target$29.00 Potential Upside/Downside-2.9%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.92% Return on Assets-90.00% Debt Debt-to-Equity RatioN/A Current Ratio21.83 Quick Ratio21.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book29.81Miscellaneous Outstanding Shares87,380,000Free Float69,234,000Market Cap$3.88 billion OptionableOptionable Beta1.07 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMs. Susanna Gatti High M.B.A. (Age 56)Chief Operating Officer Comp: $754.1kDr. Jonathan McNeill M.D. (Age 39)Chief Business Officer Comp: $662.34kMr. John G. Cox M.B.A. (Age 61)CEO, President & Director Dr. Romesh Subramanian Ph.D. (Age 59)Co-Founder & Advisor Comp: $565.17kMr. Richard William Scalzo M.B.A. (Age 38)Senior VP and Head of Finance & Administration Mr. John Najim M.B.A.Chief Technical OfficerDr. Oxana Beskrovnaya Ph.D. (Age 63)Chief Scientific Officer Comp: $631.08kMs. Amy Reilly (Age 50)Senior VP and Head of Corporate Communications & Investor Relations Mr. Daniel Wilson (Age 52)Senior VP & Head of Legal Ms. Kate MitchellVP & Head of Human ResourcesMore ExecutivesKey CompetitorsDicerna PharmaceuticalsNASDAQ:DRNAProtagonist TherapeuticsNASDAQ:PTGXAmphastar PharmaceuticalsNASDAQ:AMPHFive Prime TherapeuticsNASDAQ:FPRXCalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 107,233 shares on 7/26/2024Ownership: 0.356%Legato Capital Management LLCBought 4,035 shares on 7/26/2024Ownership: 0.018%China Universal Asset Management Co. Ltd.Sold 4,075 shares on 7/20/2024Ownership: 0.013%Nisa Investment Advisors LLCBought 669 shares on 7/20/2024Ownership: 0.001%Genesee Capital Advisors LLCBought 16,359 shares on 7/19/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $13.30 at the beginning of 2024. Since then, DYN shares have increased by 234.8% and is now trading at $44.53. View the best growth stocks for 2024 here. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) posted its earnings results on Thursday, May, 2nd. The company reported ($0.81) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.81). When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.36%), Raymond James & Associates (0.12%), Genesee Capital Advisors LLC (0.02%) and Legato Capital Management LLC (0.02%). Insiders that own company stock include Dirk Kersten, Venture Fund Xi LP Atlas, Joshua T Brumm, Wildon Farwell, Susanna Gatti High, Oxana Beskrovnaya, Jonathan Mcneill and Richard William Scalzo. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DYN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DYN Stock Alerts